Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ-151 in adults with chronic plaque psoriasis
NCT03392168Phase 2Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of roflumilast in plaque psoriasis, sponsored by Arcutis Biotherapeutics. Started Dec 2017; status: completed.
02
Drugs
roflumilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03392168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392168.